Current and Emerging Therapies for COVID-19 in Lung Transplantation.
Daniel Z P FriedmanNatasha N PettitErica MacKenzieJennifer PisanoPublished in: Current pulmonology reports (2023)
Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.